key: cord-1017807-s8gzeh6i
authors: Sathyavadhi, Anveshi; Gupta, Anand; Avadhanam, Vishnu Mahathi; Lakkireddygari, Siva Kumar Reddy
title: Intracranial hemorrhage in a patient with severe COVID-19 acute respiratory distress syndrome on Veno-venous extra corporeal membrane oxygenation: A case report()
date: 2021-12-03
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.103033
sha: 8002de6b19497bca8784a72b32611d376187cbb5
doc_id: 1017807
cord_uid: s8gzeh6i

INTRODUCTION AND IMPORTANCE: COVID-19 can lead to severe acute respiratory distress syndrome (ARDS) where Veno-Venous Extra Corporeal Membrane Oxygenation (V–V ECMO) may be utilized for patients with severe respiratory failure. Our case report highlights a life threatening complication of V–V ECMO - intracranial hemorrhage (ICH), in a patient being treated for severe COVID-19 ARDS. CASE PRESENTATION: A 41-year-old male of Indian ethnicity with no known comorbidities presented with an 8 day history of fever and dyspnoea. The patient was diagnosed with COVID-19 through a positive RT PCR test and his clinical condition progressively deteriorated requiring mechanical ventilation. Inspite of lung protective ventilation strategies and prone ventilation, there was no improvement in oxygenation. Therefore, the patient was placed on extra corporeal life support. On day three of V–V ECMO, the patient developed anisocoria and his GCS dropped to E1VTM1. A non-contrast CT brain scan revealed a large intraparenchymal hemorrhage in the right frontoparietal lobe with an extension into the right lateral and third ventricles leading to an emergency decompressive craniectomy with lax duroplasty.Post intracranial hemorrhage,ECMO support was continued without systemic anticoagulation. Despite a transient improvement in his GCS post surgery, the patient eventually succumbed to refractory septic shock with multi organ dysfunction syndrome. CLINICAL DISCUSSION AND CONCLUSION: Balancing anticoagulation therapy is one of the biggest challenges in managing ECMO support for COVID-19 ARDS. ICH is a rare and potentially fatal complication of V–V ECMO with an apparently higher incidence among COVID-19 patients. Neurosurgical procedures may be considered in such patients when no other possible management strategies are available (and the risk of death is imminent).

COVID-19 can lead to severe ARDS where V-V ECMO is utilized for patients with severe respiratory failure. Latest guidelines by ELSO (Extracorporeal Life Support Organization) concluded that the expected outcomes for COVID-19 patients are comparable to patients supported with V-V ECMO in the pre-pandemic era.(1) The incidence of central nervous system hemorrhage as a complication of ECMO in the ARDS cohort of COVID 19 patients as per the ELSO registry is 7%.(2) ICH is a well documented complication in adults on ECMO life support and is associated with high mortality. Evidence indicates that ICH is caused by both pre-ECMO morbidity and ECMO -induced disruption of coagulation. Management during ECMO requires striking a balance between pro-and anticoagulatory demands. Neurosurgical intervention can lead to severe morbidity but has been selectively successful in some cases. (3) We present a case report of a 41-year-old male with severe COVID-19 ARDS who developed intracranial hemorrhage on day 3 after initiation of V-V ECMO and subsequently underwent emergency neurosurgery. Globally, there are few documented case series of surgical intervention for ICH in patients on extra corporeal life support without systemic anticoagulation especially in COVID-19. To our knowledge, this is the first published case report of neurosurgery performed on a patient while on VV ECMO in India.

A 41-year-old male of Indian ethnicity with no comorbidities presented with an 8 day history of fever and dyspnoea. His COVID-19 RT PCR test was positive. He did not have any significant past medical or surgical history. He had no known drug allergies. He was not on any medication at the time of presentation. His family history was not significant for any inheritable conditions. There was no history of alcohol consumption or smoking. He initially received treatment at a local hospital where his oxygen requirement at admission was 15 lit O2/ min via a non-rebreathing mask. HRCT chest scan done on day 8 of illness showed CT severity score of 14/25. A repeat HRCT chest scan done on day 15 of illness showed a CT severity score of 20/25. Due to worsening hypoxia and tachycardia, CT pulmonary angiogram was done on day 20 of illness which was negative for pulmonary thromboembolism. His oxygen support was extended to intermittent non-invasive ventilation (NIV). On day 26 of illness, he developed severe respiratory distress and was placed on mechanical ventilator support.

At this stage, he was shifted to our hospital for extra corporeal life support. At the time of referral, he was on ventilator support with 90% FiO2 and a PEEP of 10. P/F ratio was 60 and driving pressures were 30 cms H2O. Acute Physiology and Chronic Health Evaluation (APACHE II) score was 14. He was maintained on prone ventilation for 16 hours. After the first cycle of proning, he continued to have persistent hypoxemia and carbon dioxide retention despite lung-protective ventilation. His Respiratory Extracorporeal Membrane Oxygenation Survival Prediction Score (RESP) was 3, with a predicted survival chance of 76%. A decision was made to initiate V-V ECMO (Maquet Rotaflow) on day 3 of mechanical ventilation. Cannulation was done with a doublelumen single 27F jugular venous cannula (paraglide) under transesophageal echocardiography guidance. Heparin infusion was started for anticoagulation. Monitoring of anticoagulation was done using activated clotting time (ACT) and activated partial thromboplastin time (aPTT) levels with a target range of 180-220 seconds for ACT and 60-80 seconds for aPTT. Mechanical ventilation settings were changed to ultra lung-protective ventilation. Driving pressures were adjusted to 15 cm H2O.

On day 3 of ECMO, his GCS was E1VTM1, and anisocoria was noted. A non-contrast CT brain scan revealed a large intraparenchymal hemorrhage (figure 1). The ECMO run continued hereafter without heparin and prophylactic levetiracetam was added to prevent seizures. ACT levels were noted to be in the range of 140-170 sec. A decision to proceed with decompressive craniectomy was taken by the neurosurgery team. After taking consent surgery was performed by the chief of neurosurgery under general anaesthesia at our hospital, which is a multi-specialty tertiary care center. Preoperatively coagulation parameters included a platelet count of 1.5 lakh cells/mm3, ACT of 150 seconds, aPTT of 30 seconds, an INR of 1.2. Within 3 hours of diagnosis of the ICH, right frontotemporoparietal decompressive craniectomy was done with lax duroplasty.

On postoperative day 4 (day 8 of V-V ECMO), the patient showed spontaneous eyeopening and non-purposeful movements of the right upper limb (with a power of 3/5) and lower limb (with a power of 1/5). However, on day 9 of V-V ECMO, the patient developed septic shock. Blood cultures were positive for E.coli and multi-drug resistant Klebsiella pneumoniae. Antibiotic therapy was escalated as per culture and sensitivity reports and inotrope support was initiated. Despite aggressive invasive organsupportive care the patient progressively deteriorated and eventually succumbed due to refractory septic shock with multi-organ dysfunction syndrome on day 12 of V-V ECMO.

The strength of this case lies in the continuation of the ECMO run for 7 days without further complications and without systemic anticoagulation after the ICH was discovered. Neurosurgery was performed while the patient was on ECMO without anticoagulation. The cause of death of this patient was not due to the neurosurgical intervention itself, but due to septic shock one week later. The case was managed by a multidisciplinary team of intensivists, neurosurgeons, perfusionists, respiratory therapists and expert nursing staff. The limitation is that this is a single center observation limited to one case. Out of 5 V-V ECMO runs for severe COVID-19 ARDS at our center, 2 patients had ICH. One patient succumbed before intervention and the other patient is the subject of this case report. Therefore, our findings cannot be extrapolated to the general population.

The incidence of ICH during V-V ECMO for COVID-19 patients is reported to be higher when compared to non-COVID V-V ECMO runs. An early case series by Usman et al reported 4 out of 10 COVID-19 patients (40%) with devastating intracranial hemorrhage on V-V ECMO. This was significantly higher than seen previously at the authors' institution; where there was less than 1% intracranial hemorrhage during non-COVID lung rescue VV ECMO. Neurosurgical procedures in patients on anticoagulation carry a high risk of mortality. However, it may be considered in patients where no other possible management strategies are available and the risk of death is imminent.(6) Prinz et al reported high mortality of ECMO-associated, space-occupying ICH requiring surgical evacuation; however, they pointed out that the detrimental effect of the surgical procedure is even less than the detrimental effect of the space-occupying hematoma itself. Their analysis of neurosurgical relevant ICHs showed an overall mortality rate as high as 80%. (7) Based on this, we made a decision to take our patient up for neurosurgery while on V-V ECMO. Post-surgery, we decided to continue ECMO support for our patient without anticoagulation and used thromboelastography (TEG) for monitoring.

Fletcher-Sandersjöö et al described the possible pathophysiology of ICH in patients on V-V ECMO and proposed that it might involve an alteration in hemostasis as a likely significant mechanism. ECMO support itself results in thrombocytopenia, factor XIII deficiency, acquired von Willebrand syndrome, fibrinogen deficiency, and pump-induced platelet dysfunction. However, we did not observe most of these findings in our patient. They also discussed pre-ECMO factors that may also play a role in ICH development. In V-V ECMO, abrupt CO2, or O2 changes at ECMO cannulation can disrupt cerebral perfusion, which is further decreased by the use of potent sedatives, and has been linked to cerebral desaturation during ECMO initiation, as well as impairing cerebral autoregulation which in turn can precede ischemic stroke leading to ICH.(3)

The determinants of mortality in patients with ICH on V-V ECMO as per Prinz et al confirmed the independent effect of a larger ICH volume, coagulation that is not normalized within 12 hours after ICH onset, presence of intraventricular hemorrhage (IVH), larger surgical intervention, and a fluid level inside the ICH. 7 Our patient had 3 out of the above 5 parameters -large ICH volume (175 ml), larger surgical intervention (decompressive hemicraniectomy) and presence of IVH. As per another study, the factors influencing 30-day mortality in patients with ICH while on V-V ECMO included -a significantly low level of consciousness at ICH diagnosis, presence of intraparenchymal hemorrhage (IPH), large IPH volume (>38 ml), presence of IVH, Subarachnoid Hemorrhage (SAH) Fisher grade (4), hydrocephalus, midline shift (0-11 mm) and absent basal cisterns. 6 Our patient fulfilled 6 of the above 8 parameters. The unfavorable outcome of our patient is in line with the findings of previous studies. The lack of change in ECMO anticoagulation regimens might be one of the reasons behind the stagnation in rates of ICH occurrence and mortality.(8)

Our case report highlights that neurosurgical interventions can be safely performed on patients on extra corporeal life support although there is a risk of mortality. The detrimental effects of the surgery are lower than the detrimental effects of the ICH. Extra corporeal life support can be run without anticoagulation in patients who have severe active bleeding or at high risk of bleeding. This case adds to the evolving experience of the challenges faced in balancing anticoagulation therapy during extra corporeal life support. Close monitoring of all hematologic parameters is recommended during ECMO support along with a low threshold for neuroimaging. Larger, multicenter studies are warranted to evaluate the long-term feasibility of ECMO without systemic anticoagulation. 

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval was taken from the institutional ethics committee.

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Our case report highlights continuation of the ECMO run for 7 days without further complications and without systemic anticoagulation after the ICH was discovered.

Neurosurgery was performed while the patient was on ECMO without anticoagulation. The cause of death of this patient was not due to the neurosurgical intervention itself, but due to septic shock one week later.

The determinants of mortality in patients with ICH on V-V ECMO confirms the independent effect of -a larger ICH volume, coagulation that is not normalized within 12 hours after ICH onset, presence of IVH, larger surgical intervention, and a fluid level inside the ICH. Our patient had 3 out of these 5 parameters (large ICH volume (175 ml), larger surgical intervention (decompressive hemicraniectomy) and presence of IVH. • Close monitoring of haematological parameters was done using thromboelastography (TEG), activated clotting time (ACT), activated partial thromboplastin time (aPTT)

Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization

Extracorporeal Life Support Organization

Outcome, and Predictors of Intracranial Hemorrhage in Adult Patients on Extracorporeal Membrane Oxygenation: A Systematic and Narrative Review

A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19

A Double-Edged Sword: Neurologic Complications and Mortality in Extracorporeal Membrane Oxygenation Therapy for COVID-19-Related Severe Acute Respiratory Distress Syndrome at a Tertiary Care Center

Management of intracranial hemorrhage in adult patients on extracorporeal membrane oxygenation (ECMO): An observational cohort study

Clinical management and outcome of adult patients with extracorporeal life support device-associated intracerebral hemorrhage-a neurocritical perspective and grading

Neurologic Injury in Adults Supported With Veno-Venous Extracorporeal Membrane Oxygenation for Respiratory Failure

The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.This case report did not receive any funding.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written informed consent was obtained. A copy is available for review by the Editor-in-Chief of this journal on request.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. 

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry: Not applicable • Unique Identifying number or registration ID: Not applicable • Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable J o u r n a l P r e -p r o o f

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Dr Anveshi Sathyavadhi J o u r n a l P r e -p r o o f